[Porphyria cutanea tarda caused by methotrexate and buthiopurine therapy].
In a patient with psoriatic erythroderma treated with Methotrexate and later with Buthiopurine, porphyrinuria and later porphyria cutanea tarda developed, following a toxic reaction with bone marrow suppression. Hepatological examination before therapy did not reveal any signs of active liver disease.
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D011164:Porphyrias / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy
D000970:Antineoplastic Agents; D015122:Mercaptopurine; C004623:buthiopurine; D008727:Methotrexate
Porphyria cutanea tarda (PCT) als Folge der Methotrexat- und Buthiopurin-Therapie.